JAK Inhibitor Drugs May Worsen Hearing Damage From Common Antibiotics
New research reveals JAK inhibitors significantly increase hearing loss when combined with aminoglycoside antibiotics.
Summary
Researchers discovered that JAK inhibitor medications dramatically worsen hearing damage when taken alongside aminoglycoside antibiotics like kanamycin. In mouse studies, animals receiving both drug types experienced significantly greater hearing loss and cochlear damage compared to those receiving antibiotics alone. JAK inhibitors are increasingly prescribed for inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The findings suggest patients on these medications may face heightened risk of permanent hearing damage during antibiotic treatment, highlighting an important drug interaction that wasn't previously understood.
Detailed Summary
A groundbreaking study reveals that JAK inhibitor medications significantly amplify hearing damage caused by aminoglycoside antibiotics, raising important safety concerns for millions of patients. JAK inhibitors have seen explosive growth since 2018, with FDA approvals expanding from blood cancers to common inflammatory conditions like rheumatoid arthritis and ulcerative colitis.
Researchers used specially bred mice to test interactions between kanamycin (an aminoglycoside antibiotic) and momelotinib (a JAK1/JAK2 inhibitor). Animals received either kanamycin alone or combined with the JAK inhibitor over 14 days, with some groups also receiving inflammatory stimulation to mimic real-world infection scenarios.
The results were striking: mice receiving both medications experienced dramatically worse hearing loss and cochlear damage compared to those receiving antibiotics alone. Comprehensive hearing tests and microscopic examination of inner ear structures confirmed the enhanced toxicity.
For longevity-focused individuals, this research highlights a critical drug interaction that could permanently compromise hearing health. Aminoglycosides are commonly prescribed for serious bacterial infections, while JAK inhibitors represent a growing class of anti-inflammatory medications. The combination appears to overwhelm the inner ear's protective mechanisms.
The findings suggest patients on JAK inhibitors should discuss alternative antibiotic options with healthcare providers when possible. Since hearing loss significantly impacts quality of life and cognitive function as we age, protecting auditory health becomes crucial for successful longevity strategies. However, this was an animal study, and human responses may differ in magnitude or mechanism.
Key Findings
- JAK inhibitors dramatically increased hearing loss when combined with aminoglycoside antibiotics
- Cochlear damage was significantly worse in animals receiving both drug types
- The interaction occurred even with lower doses of JAK inhibitor medication
- Both hearing function tests and cellular damage confirmed the enhanced toxicity
Methodology
Researchers used genetically modified C57Bl/6N mice treated with kanamycin alone or combined with momelotinib (JAK1/JAK2 inhibitor) for 14 days. Hearing function was assessed using auditory brainstem response testing and otoacoustic emissions, while cochlear damage was evaluated through microscopic hair cell analysis.
Study Limitations
This study was conducted in mice, so human responses may differ significantly. The research used specific doses and treatment durations that may not reflect typical clinical scenarios, and long-term effects weren't evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.